Additional file 1 of Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

Greenberg, Ross S.; Ruddy, Jake A.; Boyarsky, Brian J.; Werbel, William A.; Garonzik-Wang, Jacqueline M.; Segev, Dorry L.; Imus, Philip H.

doi:10.6084/m9.figshare.17696394.v1

12885_2021_9097_MOESM1_ESM.pptx (164.97 kB)

Additional file 1 of Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

presentation

posted on 2021-12-28, 04:18 authored by Ross S. Greenberg, Jake A. Ruddy, Brian J. Boyarsky, William A. Werbel, Jacqueline M. Garonzik-Wang, Dorry L. Segev, Philip H. Imus

Additional file 1: Supplemental Figure 1. Local site and systemic adverse reactions in 44 patients with multiple myeloma within 7 days of dose 1 and dose 2 of the SARS-CoV-2 mRNA vaccine. Supplemental Table 1. Anti-SARS-CoV-2 RBD antibody titer of 44 patients multiple myeloma 1 month after two-dose SARS-CoV-2 mRNA vaccination by demographics and clinical characteristics.